Abstract 174P
Background
Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival of <12%. Patients typically present with advanced disease. Developing a blood-based screening panel could offer a simple test without requiring invasive procedures, enabling earlier detection and accelerate drug discovery. This study integrated plasma-based proteomic, tissue and clinical data supported by the PURPLE pancreatic cancer registry to identify novel biomarkers that can aid screening for early-stage disease, predict survival outcomes and guide drug discovery.
Methods
Unbiased quantitative comparative proteomics analysis was performed via a 16-window diaPASEF method on a TIMS TOF Pro mass spectrometer. Data was searched with DIA-NN (v1.8.3) in library-free mode and normalisation using RUVIIIC (v1.0.19). Matched clinicopathological and survival data was extracted from the PURPLE pancreatic cancer registry.
Results
Proteomic analysis of plasma from 203 participants showed distinct protein changes between PDAC patients with early and late-disease stage. Plasma from 120 PDAC, 69 healthy controls and 14 alternative pancreatic pathologies were analysed. A total of 919 proteins were detected (mean of 400 in each sample). When comparing PDAC with healthy controls, 246 significant differentially expressed proteins were identified (false discovery rate, FDR <0.1). Hierarchical data clustering analysis demonstrated a clear protein signature of the top 40 differentially expressed proteins in PDAC. When comparing early versus late-stage PDAC, 12 significantly differentially expressed proteins were identified. Reactome pathway analysis revealed significant up-regulation in immune response and wound healing pathways, and down-regulation of lipid and glucose metabolism in PDAC. These findings suggest that abnormal processes are quantifiable and can be detected earlier in the blood.
Conclusions
A unique PDAC protein signature was identified when comparing PDAC to healthy controls and alternative pancreatic pathologies. The dysregulated proteins identified have potential therapeutic implications that could accelerate selection of drug targets, inform clinical trial design, and enable earlier blood-based PDAC screening.
Clinical trial identification
Australian New Zealand Clinical Trial Registy Trial Acronym: PURPLE Registry Pancreatic cancer: Understanding Routine Practice and Lifting End Results (PURPLE). A Prospective Pancreatic Cancer Clinical Registry Registration number: ACTRN12617001474347 Registered: 08/03/2017.
Editorial acknowledgement
Legal entity responsible for the study
Walter & Eliza Hall Institute.
Funding
Hemstritch Centenary Fellowship ( Awarded to Dr Belinda Lee), Philanthropic funding from the Hemstritch Foundation & Segal Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract